Drug Profile
Research programme: cyclin-dependent kinase 9 inhibitors - AstraZeneca
Latest Information Update: 17 Jun 2019
Price :
$50
*
At a glance
- Originator Probiodrug
- Developer AstraZeneca
- Class Small molecules
- Mechanism of Action Cyclin dependent kinase 9 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Inflammation
Most Recent Events
- 11 Jun 2019 Probiodrug is now called Vivoryon Therapeutics
- 28 Jul 2018 No recent reports of development identified for preclinical development in Cancer in Unknown
- 16 Jul 2016 No recent reports of development identified for preclinical development in Inflammation in Germany